IDH3A and glioblastoma: From June 2018 to November 2019, we enrolled 12 patients with isocitrate dehydrogenase–wildtype glioblastoma in the study; 5 were analyzed in part A and 7 in part B. The first patient in part A withdrew from the intervention of receiving avelumab after experiencing rigors during the first infusion, a known side effect of the drug that was easily controlled with supportive measures.